AstraZeneca acknowledges Rare Side Effects of COVID-19 Vaccine - Understanding Thrombocytopenia Syndrome.
Learn about AstraZeneca's acknowledgement of rare side effects from its Covishield COVID vaccine and the implications for vaccine safety.
image for illustrative purpose
A significant revelation has come to light regarding the Covishield COVID vaccine and its potential rare side effects, raising concerns among health experts. AstraZeneca, the British-Swedish multinational pharmaceutical and Biotechnology Company, has admitted in court documents that its COVID vaccine, Covishield, can lead to a rare condition known as Thrombosis with Thrombocytopenia Syndrome (TTS).
Covishield, developed by AstraZeneca and manufactured by the Serum Institute of India, was widely used in India as part of the COVID vaccination campaign. However, recent developments have drawn attention to the potential risks associated with its administration.
TTS is a serious and uncommon condition characterised by the formation of blood clots (thrombosis) accompanied by low platelet counts (thrombocytopenia). Symptoms of TTS may include severe abdominal pain, headaches, shortness of breath, swelling in the legs, and neurological issues. Diagnosis typically involves blood tests to assess platelet levels and imaging studies to detect blood clots.
In response to these revelations, AstraZeneca has faced legal action in the UK, with 51 cases filed against the company alleging that its vaccine has caused deaths. In court documents, AstraZeneca acknowledged that Covishield can, in very rare cases, lead to TTS. This admission highlights the importance of understanding and addressing the potential risks associated with COVID vaccination.
Healthcare providers emphasise the need for vigilance in monitoring individuals who receive the Covishield vaccine for any signs or symptoms of TTS. Prompt recognition and appropriate management are crucial for improving outcomes in cases of this rare but serious syndrome.
Dr. Rajeev Jayadevan, a medical expert, explained that TTS can occur rarely following certain types of vaccines, including adenovirus vector vaccines like Covishield. While COVID vaccines have played a crucial role in preventing deaths, it's essential to acknowledge and address these extremely rare but potentially serious adverse events.
The World Health Organization (WHO) highlighted TTS as a new adverse event following immunisation in individuals who received COVID-19 non-replicant adenovirus vector-based vaccines, including AstraZeneca's ChAdOx-1 vaccine. This recognition highlights the need for continued monitoring and assessment of vaccine safety.
